

## REMARKS

Applicants acknowledge the allowance of claims 87, 100-104, 108, 111-115 and 117 and the finding that claims 93, 109 and 118-119 would be allowable in independent form.

### Claim Amendments

Claims 93, 109 and 118-119 have been made independent by the amendments above and all rejected claims (claims 74, 81, 106 and 107) have been cancelled. Allowed claim 108 has been amended to recite only one of the listed compounds to focus the claim on the commercial product Nexavar ®. Allowed claim 117 has been cancelled to avoid overlap with the claims in co-pending application number 11/768,104. All claims, including allowed claims 83 and 108, have been amended to recite an effective amount of the compound(s) administered. These amendments after final do not raise new issues and are appropriate under 37 CFR 1.116.

With the above amendments, applicants submit the application is in condition for allowance.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

/Richard J. Traverso/

\_\_\_\_\_  
Richard J. Traverso, Reg. No. 30,595  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 812 5310  
**Attorney Docket No.: BAYER-0018-A**  
**Filed April 25, 2011**